Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Russian Bear who wrote (982)	5/14/1998 2:06:00 PM
From: Diamondcutter	Read Replies (1) \| Respond to of 1826

"MGI Pharma Cancer Drug Eliminates Human Tumors In Mice" hit the Dow Jones wire at 3:09 PM. I'm surprised it took an entire minute for traders to jump on it! (Scrolling headlines are wonderful) Diamondcutter

To: Russian Bear who wrote (982)	5/14/1998 2:35:00 PM
From: bocaburgerman	Respond to of 1826

May 14, 1998/FOOLWIRE/ -- MGI Pharmaceuticals (Nasdaq: MOGN) gave back $2 1/16 to $10 3/4 after the company's 65% advance yesterday that came about due to management remarks at its annual meeting about its anticancer drug, MG 114. Chief Operating Officer James V. Adam told shareholders that the company believes MG 114 is "... just as promising, and just as unproven, as other cancer therapies recently discussed in the media." Adam is talking about EntreMed's (Nasdaq: ENMD) anticancer drugs, which were highlighted in a New York Times piece that drove its stock up dramatically in one day.

To: Russian Bear who wrote (982)	5/15/1998 1:20:00 PM
From: seminole	Read Replies (1) \| Respond to of 1826

Mr Bear I spent the last three days at Disneyland. (No papers and no news) I think the volume was more interesting than the price change. While I would assume that those big thinkers with big institutional money followed the price up, I wonder if any of this buying could be MGI's potential Euro partner. This stock could go to $100/sh and would still hold until I see that Phase II data. crazy like a fox and in at $4 richard